2023
Laryngeal dystonia: Phenomenology, genetics, and management
Blitzer A, Kohli N. Laryngeal dystonia: Phenomenology, genetics, and management. Toxicon 2023, 233: 107258. PMID: 37647998, DOI: 10.1016/j.toxicon.2023.107258.Peer-Reviewed Original ResearchConceptsLaryngeal dystoniaMovement disordersOnabotulinum toxin APosterior cricoarytenoid muscleRare movement disorderTask-specific movement disorderEndoscopic findingsCricoarytenoid muscleBotulinum toxinAbnormal movementsToxin AThyroarytenoid muscleDystoniaAbductor musclesPatientsTreatment resultsDisordersNormal functionVocal foldsMuscleToxinSymptomsIncidenceLarynxFirst use
2021
25447 Baricitinib treatment results in clinically meaningful itch reduction and enhanced quality of life in patients with moderate-to-severe atopic dermatitis: Results from BREEZE-AD5
Kwatra S, Forman S, Cruz A, Ball S, DeLozier A, Pierce E, Buchanan A, Sun L, Ding Y, Strober B. 25447 Baricitinib treatment results in clinically meaningful itch reduction and enhanced quality of life in patients with moderate-to-severe atopic dermatitis: Results from BREEZE-AD5. Journal Of The American Academy Of Dermatology 2021, 85: ab59. DOI: 10.1016/j.jaad.2021.06.260.Peer-Reviewed Original Research
2020
Corrigendum to “Icon immunoconjugate treatment results in regression of red lesions in a non-human primate (Papio anubis) model of endometriosis” [Reprod. Biol. 18 (2018) 109–114]
Hufnagel D, Goetz LG, Hu Z, Nyachieo A, D'Hooghe T, Fazleabas A, Duleba A, Krikun G, Taylor HS, Lockwood CJ. Corrigendum to “Icon immunoconjugate treatment results in regression of red lesions in a non-human primate (Papio anubis) model of endometriosis” [Reprod. Biol. 18 (2018) 109–114]. Reproductive Biology 2020, 20: 600. PMID: 32900640, DOI: 10.1016/j.repbio.2020.08.005.Peer-Reviewed Original Research
2019
Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma
Magni M, Biancon G, Rizzitano S, Cavanè A, Paolizzi C, Dugo M, Corradini P, Carniti C. Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma. British Journal Of Cancer 2019, 121: 567-577. PMID: 31474759, PMCID: PMC6889385, DOI: 10.1038/s41416-019-0557-8.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisCell CycleCell SurvivalCyclophosphamideDasatinibDoxorubicinDrug Administration ScheduleDrug SynergismEtoposideGene ExpressionGene Expression ProfilingHumansJurkat CellsLymphoma, T-CellMice, Inbred NODMice, SCIDPrednisoneProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene Proteins c-fynReceptors, Antigen, T-CellrhoA GTP-Binding ProteinTreatment OutcomeUp-RegulationVincristineConceptsT-cell lymphomaPeripheral T-cell lymphomaDrug combinationsTyrosine kinase inhibitor dasatinibVivo xenograft mouse modelMalignant T-cell linesXenograft mouse modelTyrosine kinase inhibitionTumor growth inhibitionKinase inhibitor dasatinibT cell receptorT cell linesT-cell receptor pathwayCell cycle distributionWestern blot analysisChemotherapy efficacyPreclinical modelsConclusionsOur dataMouse modelVivo effectsXenograft modelClinical testingTreatment resultsInhibitor dasatinibLymphoma
2018
Herpes simplex virus 1 infection and valacyclovir treatment in schizophrenia: Results from the VISTA study
Breier A, Buchanan RW, D'Souza D, Nuechterlein K, Marder S, Dunn W, Preskorn S, Macaluso M, Wurfel B, Maguire G, Kakar R, Highum D, Hoffmeyer D, Coskinas E, Litman R, Vohs JL, Radnovich A, Francis MM, Metzler E, Visco A, Mehdiyoun N, Yang Z, Zhang Y, Yolken RH, Dickerson FB. Herpes simplex virus 1 infection and valacyclovir treatment in schizophrenia: Results from the VISTA study. Schizophrenia Research 2018, 206: 291-299. PMID: 30478008, DOI: 10.1016/j.schres.2018.11.002.Peer-Reviewed Original ResearchConceptsHSV-1Double-blind efficacy trialHerpes simplex virus 1 (HSV-1) infectionEarly phase schizophreniaSimplex virus 1 infectionVirus-1 infectionPathophysiology of schizophreniaPrimary endpointValacyclovir treatmentNegative subjectsRecent trialsVISTA studyEfficacy trialsLetter-Number Sequencing TestNegative groupPositive groupSevere formHerpes virusPositive symptomsMore impairmentTreatment resultsUS sitesCognitive deficitsNon-activated stateSchizophreniaIcon immunoconjugate treatment results in regression of red lesions in a non-human primate (Papio anubis) model of endometriosis
Hufnagel D, Goetz L, Hu Z, Nyachieo A, D’Hooghe T, Fazleabas A, Duleba A, Krikun G, Taylor HS, Lockwood CJ. Icon immunoconjugate treatment results in regression of red lesions in a non-human primate (Papio anubis) model of endometriosis. Reproductive Biology 2018, 18: 109-114. PMID: 29422377, DOI: 10.1016/j.repbio.2018.01.009.Peer-Reviewed Original ResearchMeSH KeywordsAdenoviridaeAdnexal DiseasesAmino Acid SubstitutionAnimalsEndometriosisFactor VIIFemaleGenetic TherapyGenetic VectorsHumansImmunoconjugatesImmunoglobulin Fc FragmentsImmunoglobulin GMolecular Targeted TherapyMutationNeovascularization, PathologicPapio anubisPelvisPeptide FragmentsRandom AllocationRecombinant Fusion ProteinsThromboplastinConceptsNon-human primatesNovel treatmentsTissue factorNon-human primate modelRegression of endometriosisEctopic endometrial tissueReproductive-aged womenEctopic endometrial lesionsWeekly intraperitoneal injectionsFactor VII/VIIaLesion vasculatureChronic painEndometrial lesionsEndometrial tissueEndometriosis lesionsLaparoscopic confirmationSurgical inductionIntraperitoneal injectionPrimate modelCommon conditionMurine modelEndometriosisTreatment groupsControl groupTreatment results
2015
The Effect of Menopausal Hormone Therapies on Breast Cancer Avoiding the Risk
Flores VA, Taylor HS. The Effect of Menopausal Hormone Therapies on Breast Cancer Avoiding the Risk. Endocrinology And Metabolism Clinics Of North America 2015, 44: 587-602. PMID: 26316245, PMCID: PMC4555991, DOI: 10.1016/j.ecl.2015.05.007.Peer-Reviewed Original Research
2014
The Immune System and Electroconvulsive Therapy for Depression
Guloksuz S, Rutten B, Arts B, van Os J, Kenis G. The Immune System and Electroconvulsive Therapy for Depression. Journal Of Ect 2014, 30: 132-137. PMID: 24755720, DOI: 10.1097/yct.0000000000000127.Peer-Reviewed Original ResearchConceptsEffects of ECTElectroconvulsive therapyImmune systemMechanism of actionImmune activationImmune functioningImpact of ECTTherapeutic actionTreatment-resistant depressionTransient immune activationPubMed/MEDLINEPossible roleImmunological changesCytokine concentrationsAdrenal axisTreatment optionsLarger sample sizeTreatment resultsPsychiatric conditionsSingle sessionRelevant articlesDefinitive conclusionsSearch termsSample sizeDepression
2012
The Abl and Arg Kinases Mediate Distinct Modes of Phagocytosis and Are Required for Maximal Leishmania Infection
Wetzel DM, McMahon-Pratt D, Koleske AJ. The Abl and Arg Kinases Mediate Distinct Modes of Phagocytosis and Are Required for Maximal Leishmania Infection. Molecular And Cellular Biology 2012, 32: 3176-3186. PMID: 22665498, PMCID: PMC3434515, DOI: 10.1128/mcb.00086-12.Peer-Reviewed Original ResearchConceptsComplement receptor 3Leishmania infectionIgG-coated beadsMurine cutaneous leishmaniasisPotential therapeutic targetLeishmania uptakeVisceral diseaseObligate intracellular parasitesCutaneous leishmaniasisTherapeutic targetFc receptorsAmastigote uptakeTreatment resultsReceptor 3Small lesionsInfection severityLeishmania amazonensisKinase inhibitorsIntracellular parasitesBead phagocytosisPhagocytosisReceptorsC3biInfectionLeishmaniasisImatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro.
Hinchcliff M, Huang CC, Ishida W, Fang F, Lee J, Jafari N, Wilkes M, Bhattacharyya S, Leof E, Varga J. Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro. Clinical And Experimental Rheumatology 2012, 30: s86-96. PMID: 22691216, PMCID: PMC3860597.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBenzamidesBiopsyCase-Control StudiesCells, CulturedFibroblastsFibrosisGene Expression ProfilingGene Expression RegulationHumansImatinib MesylateMiceMice, KnockoutOligonucleotide Array Sequence AnalysisPhosphorylationPiperazinesProtein Kinase InhibitorsProto-Oncogene Proteins c-ablPyrimidinesScleroderma, SystemicSignal TransductionSkinTime FactorsTranscription, GeneticTransforming Growth Factor beta1ConceptsSystemic sclerosisSSc fibroblastsSkin biopsiesInternal organ fibrosisHeterogeneous multifactorial diseaseControl fibroblastsControl skin biopsiesFibrotic gene expressionSystemic sclerosis fibroblastsC-AblProgressive skinAntifibrotic effectsImatinib mesylateHealthy controlsCardiovascular diseaseGene expressionHealthy subjectsFibrotic responseCholesterol metabolismOrgan fibrosisC-Abl activationMultifactorial diseaseTreatment resultsTissue levelsFibrosis
2010
Development of Quantitative Molecular Clinical End Points for siRNA Clinical Trials
Hickerson RP, Leachman SA, Pho LN, Gonzalez-Gonzalez E, Smith FJ, McLean WH, Contag CH, Leake D, Milstone LM, Kaspar RL. Development of Quantitative Molecular Clinical End Points for siRNA Clinical Trials. Journal Of Investigative Dermatology 2010, 131: 1029-1036. PMID: 21191405, DOI: 10.1038/jid.2010.372.Peer-Reviewed Original ResearchConceptsClinical trialsPachyonychia congenitaEnd pointPhase 1b clinical trialClinical end pointsRare skin disorderMolecular end pointsTypes of trialsImmune surveillancePatient-derived keratinocytesSkin disordersSustained inhibitionTreatment resultsRNAi-based therapeuticsRNA interferenceMRNA levelsTrialsTotal RNAHuman skinKeratinocyte culturesMRNAAmplifiable mRNATherapeuticsInhibitorsInhibition
2005
Patient-Based Outcomes Following Clubfoot Surgery
Vitale MG, Choe JC, Vitale MA, Lee FY, Hyman JE, Roye DP. Patient-Based Outcomes Following Clubfoot Surgery. Journal Of Pediatric Orthopaedics 2005, 25: 533-538. PMID: 15958910, DOI: 10.1097/01.bpo.0000157999.38424.ba.Peer-Reviewed Original ResearchConceptsPatient-based measuresClubfoot surgeryChild Health QuestionnaireDisease-specific instrumentLong-term outcomesPatient-based outcomesDisease-specific measuresCohort of adolescentsQuality of lifePrimary endpointSurgical repairPractice patternsHealth QuestionnaireAppropriate treatmentAuthors' institutionRadiographic measuresHealth outcomesTreatment resultsHealthy feetYoung athletesPatientsSurgeryOutcomesOngoing controversySimilar results
2003
Premenstrual disorders: bridging research and clinical reality
Yonkers KA, Pearlstein T, Rosenheck RA. Premenstrual disorders: bridging research and clinical reality. Archives Of Women's Mental Health 2003, 6: 287-292. PMID: 14628181, DOI: 10.1007/s00737-003-0026-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultConnecticutDepressive DisorderDiagnostic and Statistical Manual of Mental DisordersFemaleHumansPatient Acceptance of Health CarePatient SelectionPremenstrual SyndromePsychiatric Status Rating ScalesSelective Serotonin Reuptake InhibitorsSelf-AssessmentSeverity of Illness IndexSurveys and QuestionnairesTreatment OutcomeConceptsPremenstrual dysphoric disorderPremenstrual symptomsTreatment resultsBrief Patient Health QuestionnaireConcurrent psychiatric conditionsOb-gyn settingsStatistical Manual IV criteriaSerotonin reuptake inhibitorsUsual care settingsPatient Health QuestionnaireMinor depressive disorderActual clinical practiceTypes of symptomsEligible womenPatient characteristicsReuptake inhibitorsOpen trialSymptomatic subgroupCurrent comorbidityIV criteriaClinical trialsDepressive disorderHealth QuestionnaireTypical patientDysphoric disorder
1997
Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs
Grace A, Bunney B, Moore H, Todd C. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends In Neurosciences 1997, 20: 31-37. PMID: 9004417, DOI: 10.1016/s0166-2236(96)10064-3.Peer-Reviewed Original ResearchConceptsDepolarization blockAntipsychotic drugsDopamine systemNigrostriatal dopamine systemWeeks of treatmentExtrapyramidal side effectsAntipsychotic drug efficacyDopamine receptor antagonistDrug treatment resultsMesolimbic dopamine neuronsTreatment of schizophreniaDopamine neuron firingReceptor blockadeDopamine neuronsTherapeutic impactSide effectsClinical actionsDrug AdministrationTherapeutic efficacyTreatment resultsDrug efficacyTherapeutic actionPotential mechanismsDrugsEfficacy
1979
Multimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects.
WEISS R, DeVITA V. Multimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects. Annals Of Internal Medicine 1979, 91: 251-60. PMID: 380437, DOI: 10.7326/0003-4819-91-2-251.Peer-Reviewed Original ResearchConceptsDisease-free survivalPrimary treatment programGroup of patientsAdvanced diseaseTherapy regimensPrimary lesionSurgical removalAdult malignanciesPalliative treatmentTreatment resultsClinical trialsHuman trialsCancer mortalityChemotherapyMalignancyTreatment programsTreatmentRegimensPatientsLesionsCancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply